Hydralazine

Hydralazine is a direct vasodilator, a medicine taken by mouth that the label says apparently lowers blood pressure by relaxing the muscle in blood vessel walls. The US label read, for generic hydralazine hydrochloride tablets, lists essential hypertension, alone or as an adjunct (an add-on to other treatment). The label says the precise mechanism of action is not fully understood.

Also called Hydralazine hydrochloride

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 5470 (hydralazine hydrochloride is 82027); UNII FD171B778Y is the UNII of the hydrochloride salt that the label gives, so it is a broad match. MeSH descriptor D006830 is Hydralazine. RxClass lists the FDA established pharmacologic class Arteriolar Vasodilator, the class the direct vasodilators page records for minoxidil; the record is filed under that page on that evidence, and the page gained the alias Arteriolar vasodilator for it. The label read is the Chartwell RX, LLC generic tablet label, application ANDA086242, effective 2025-12-10 in openFDA, the label the class page already uses. The UNII and application number come from the openFDA record as read on 2026-11-09; the record read again on 2026-11-18 has the same effective date but no longer carries those fields. The plan row's label (set id 024ac6b8) was not read, and the combination products that contain hydralazine were not read. This page records the label indication and the mechanism sentences only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says the precise mechanism of action is not fully understood and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.

Classification codes

  • UNII FD171B778Y

Claims and evidence

Context People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets

Recipient
Recipient not specified
Population
Patients with essential hypertension, as the indications section of the label states. The label passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with essential hypertension
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct. It says the precise mechanism of action is not fully understood, and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.

    Applies to Recipient not specified People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and the combination products that contain hydralazine were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Background openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read.
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read.
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      Label passage quoted in the research quote table (HYD-LB-04).
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].clinical_pharmacology[0]
      How it applies
      Label passage quoted in the research quote table (HYD-LB-05, HYD-LB-06).
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:hydralazine
Content hash
a720f56047a97697bf4062548a20b76ce78b6557d6c413051cbce1013ae25590